Our faculty secure major research grants from various National Institutes of Health as well as private sources.
Chelsie Armbruster, PhD
Conserved Proteus mirabilis genetic requirements for colonization of the catheterized urinary tract. Chelsie Armbruster (Principal Investigator). National Institute of Diabetes and Digestive and Kidney Diseases. $1,684,580. 9/1/2019-5/1/2024.
Genetic susceptibility to mucosal infections with aging. Elsa Bou Ghanem (Co-Principal Investigator). NIAID-R21. $438,625. 6/1/2020-5/1/2022.
The efficacy of Liposomal Encapsulation of Polysaccharides pneumococcal vaccine in protecting aged hosts against invasive Streptococcus pneumoniae infections in murine models. Elsa Bou Ghanem (Co-Principal Investigator). NIA-R21. $436,310. 9/1/2019-6/1/2021.
The role of the extracellular adenosine pathway in age-driven decline in polymorphonuclear leukocyte (PMN) anti-pneumococcal responses. Elsa Bou Ghanem (Co-Principal Investigator). The University at Buffalo CTSI Translational Pilot Studies Program. $40,000. 4/1/2019-4/1/2020.
The role of extracellular adenosine in age-driven susceptibility to S. pneumoniae lung infection. Elsa Bou Ghanem (Principal Investigator). NIA-R00. $453,576. 9/1/2018-6/1/2021.
TARGETING M. CATARRHALIS FOR PREVENTION AND TREATMENT OF OTITIS MEDIA. Anthony Campagnari (Principal Investigator). National Institutes of Deafness and Communicative Disorders. $1,982,425. 5/1/2016-4/1/2021.
Pneumococcal transition from nasopharyngeal biofilm carriage to otitis media. Anthony Campagnari (Principal Investigator). NIH/NIDCD. $1,840,000. 3/1/2014-2/1/2019.
Evaluation of a Specific Cytotoxic Agent and Identification of a New Targetable Receptor for Human TripleNegative Breast Cancer. Terry Connell (Co-Investigator). Dept. of Defense, BCRP, Breakthrough Award Levels 1. $375,000. 4/1/2018-3/1/2020.
Specific induction of lethal autophagy in triple-negative breast cancer cells. Terry Connell (Principal Investigator). National Cancer Institute, NIH. $275,000. 4/1/2017-3/1/2019.
Regulation of Intrinsic Caspofungin Resistance in C. neoformans. John Panepinto (Principal Investigator). National Insitute of Allergy and Infectious Diseases. $412,353. 8/1/2018-7/1/2020.
Stress Responsive Reprogramming of Translating mRNA Pools in C. neoformans. John Panepinto (Principal Investigator). NIAID. $1,932,170. 5/1/2017-4/1/2022.
Control of Host-Induced C. neoformans Morphogenesis by Protein Arginine Methylation. John Panepinto (Principal Investigator). American Heart Association Founders Affiliate. $154,000. 1/1/2017-12/1/2019.